Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Status:
Recruiting
Trial end date:
2026-10-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy
given concomitantly with Tislelizumab and as maintenance therapy in participants with
locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital